TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stability/instability of plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trough plasma concentration of clozapine (C0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's Decisional Conflict Scale (DCS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brachial plexus compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ctDNA differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Dose-limiting-toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Antigen-specific T-cell Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-Weighted Average Change From Baseline in Spinal Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Discontinuing Study Treatment Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Drinks Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the assigned screening strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events (AE), Related AE, and AE Leading to Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Values and Electrocardiogram Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Suicidal Ideation or Behavior Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Antibiotic prescribing quality indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: non-hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Microaspiration of gastric contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes of Nt-proBNP Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Days on Which Daily N-back Sessions Were Completed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Days on Which Daily Mood Assessment Tests Were Completed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correlation Coefficient Between Measures of Cognition (N-back Scores) and Performance on the CANTAB Tests: Spatial Working Memory Between Errors (SWMBE) and Spatial Working Memory Strategy (SWMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cutaneous Reaction Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Opioid prescription use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Lean Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change From Baseline in MRI T2*
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression, Anxiety and Stress Scale - 21
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Care-related Quality of Life instrument
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Patients with Hypotensive Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dosage of Norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence and severity of local and systemic side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Accrued
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With >80% Adherence to the Protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Completed Data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intracranial pressure (ICP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency and severity of muscle cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in the total histopathological synovitis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Odds ratio for vitamin D supplementation in relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds ratio for vitamin D supplementation in patients with specific VDR genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with positive results of GBS culture or/and QF-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: General health state
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total energy intake of macronutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ectopia lentis measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Skeletal muscle mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skeletal muscle energetic decline during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cardiac muscle energetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Test performance of different diagnostic modalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioequivalence of tissue curcumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-5 Bleeding/Haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline IPAQ-SF score at 3-months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline Saint George Respiratory Questionnaire score at 3-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum tolerable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Pain Relief Score (TOTPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of antihypertensive drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerance of antihypertensive drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Cigarette Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cannabis Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholestasis in pregnancy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary tract infection incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: First Variceal Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of major metabolites of [3H]-semaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Aggregation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bleeding Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptomatic laboratory-confirmed influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropsychological assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients finishing 4 weeks of infliximab use
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Local Tolerability Symptoms According to Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of AN2728 and Major Oxidative Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare resource utilization including direct and indirect costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient reported health outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lipid Peroxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c < 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic blood pressure < 130 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL cholesterol < 100 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete Continuous Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number of urgent care visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Venous thromboembolism (VTE)- related death
Endpoint domain: Mortality/survival
Primary endpoint: Symptomatic deep-vein thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Asymptomatic proximal DVT as detected by systematic compression ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Brachial Arterial Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: volume of the uterine fibroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Anxiety Level During Regional Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Level During Regional Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Oxymetazoline and PBBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Oxymetazoline and PBBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of Oxymetazoline and PBBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Oxymetazoline and PBBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-infinity of Oxymetazoline and PBBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Knowledge Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Combined early safety and clinical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAIT parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic effect measured by Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c (%) Levels at Day 180
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 90 to Day 120
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain Infarction size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of neurological symptoms and functions (Severity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of neurological symptoms and functions (Dependence)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Change in Number of Active Joints With Arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Depression Anxiety Stress Scale -21 (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive Mental Health Scale (PMH)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PFT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MRC grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new-onset COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Health of Nations Outcomes Scale (HoNOS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Clinical Interview Schedule Revised (CIS-R) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cisplatin-induced hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Depression severity score at week 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse drug reaction severity score at week 8
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary assisted patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: secondary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in incretin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortical activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: White Blood Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peritoneal adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visibility of the tattoo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Triamcinolone Acetonide in Blood Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIPP SCALE score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Physical Activity (Weekly Minutes)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of relapse in alcohol drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the concentration versus time curve in 1 dosing interval (AUC (TAU))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clearance of renal stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in PDQ-39 single index score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Kidney Transplant Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score in the Study Eye
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comfort Rating Score in the Study Eye
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comfortable Wear Time (CWT) in the Study Eye
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Expression of skin biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Surgical-Induced Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From Randomization to Virologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From Treatment Dispensation to a Grade 3/4 Safety Event
Endpoint domain: Adverse events/effects
Primary endpoint: Time From Treatment Dispensation to Treatment Modification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-Report of Difficulties in Emotion Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of severe respiratory disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Myocardial Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral Tissue Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-vivo Soft Contact Lens Wettability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Heart Failure Related (HFR) Hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Freedom From a Device/System-related Complication (DSRC)
Endpoint domain: Adverse events/effects
Primary endpoint: Acute change in global cognitive task performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acute changes in mood; as assessed by the Bond-Lader mood scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in prospective memory performance; as assessed by a prospective memory task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent of Subjects Meeting Treatment Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conversion to long-term hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Acute Radiation Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: neutrophil content of induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Myocardial perfusion-stress/rest scores (SRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in summed stress scores (SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients experiencing hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cognitive Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Patient Reported Outcome Measurement Information System (PROMIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Health Utilities Index (HUI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical response at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot flushes severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experience an ALT and AST Value > 3.0 x ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants With Total Bilirubin > 1.5 x ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Participants With a Hypotensive Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Symptoms of Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Hyperkalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Discontinuing Study Medication
Endpoint domain: Adverse events/effects
Primary endpoint: Number of vital capacity breaths required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End tidal oxygen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Upper esophageal sphincter pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants in Each HE Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of difficult selective bronchial intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Maximal Voluntary Contraction of the Hip Flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum concentrations of fetuin-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentrations of osteoprotegrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes